NCT03821974

Brief Summary

The objective of this randomized controlled trial is to evaluate whether wet suction technique (WST), compared with dry suction technique (DST), shall present a better outcome with regard to the diagnostic yield and specimen quality of patients with solid lesions in the pancreatics.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 3, 2019

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

January 15, 2019

Completed
15 days until next milestone

First Posted

Study publicly available on registry

January 30, 2019

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2019

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2020

Completed
Last Updated

June 16, 2021

Status Verified

June 1, 2021

Enrollment Period

9 months

First QC Date

January 15, 2019

Last Update Submit

June 14, 2021

Conditions

Keywords

Pancreatic solid lesionswet suction techniquedry suction technique

Outcome Measures

Primary Outcomes (1)

  • The primary outcome is defined as the overall diagnosis yield of solid lesions by EUS-FNA with each aspiration technique.

    The primary outcome is defined as the overall diagnosis yield of solid lesions by EUS-FNA with each aspiration technique.

    20 weeks

Secondary Outcomes (4)

  • The second outcome is defined as the diagnose yield of first pass of solid lesions by EUS-FNA with each aspiration technique.

    20 weeks

  • The third outcome is the diagnose yield in benign solid lesions by EUS-FNA with each aspiration technique.

    20 weeks

  • The forth outcome is the diagnose yield in malignant solid lesions by EUS-FNA with each aspiration technique.

    20 weeks

  • The fifth outcome is the diagnose yield in solid lesions in different parts of the pancreas by EUS-FNA with each aspiration technique.

    20 weeks

Study Arms (2)

dry group

EXPERIMENTAL

The sequence of the technique of the puncture is dry-wet-dry-wet.

Procedure: wet suction techniqueProcedure: dry suction technique

wet group

EXPERIMENTAL

The sequence of the technique of the puncture is wet-dry-wet-dry.

Procedure: wet suction techniqueProcedure: dry suction technique

Interventions

For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a "locked" position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion.

dry groupwet group

For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a "locked" position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion.

dry groupwet group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \> 18 years, \< 80 years
  • female or male
  • Patients are required to undergo EUS-FNA after undergoing imaging examination (MRI, CT, or ultrasonography) which identify that the pancreatic lesions are existing and solid.
  • Agree to attend this study and signed informed consent letter

You may not qualify if:

  • bad physical condition, including hemoglobin ≤ 8.0 g/dl, severe cardiorespiratory dysfunction, and so on
  • Coagulopathy (platelet count \< 50,000/mm3, international normalized ratio \> 1.5) or having taken oral anticoagulation agents such as aspirin or warfarin in the previous week
  • Be rejected by anesthesia
  • Acute pancreatitis in the previous 2 weeks
  • Pregnant or lactation period
  • Psychiatric disease, drug addiction, or other reason for unreliable follow-up or questionnaires
  • Don't agree to attend this study and absence of informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The third Xiangya Hospital of central south University

Changsha, Hunan, 410003, China

Location

Study Officials

  • Li Tian, MD

    The Third Xiangya Hospital of Central South University

    PRINCIPAL INVESTIGATOR
  • Ting Tong, MD

    The Third Xiangya Hospital of Central South University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 15, 2019

First Posted

January 30, 2019

Study Start

January 3, 2019

Primary Completion

September 30, 2019

Study Completion

March 31, 2020

Last Updated

June 16, 2021

Record last verified: 2021-06

Data Sharing

IPD Sharing
Will not share

Locations